Advisor Group Holdings, Inc. Morpho Sys Ag Transaction History

Advisor Group Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$4.55 - $9.9 $9 - $19	-2 Reduced 18.18%	9 $0
Q3 2023 Nov 13, 2023	SELL	$6.72 - $8.6 $13 - $17	-2 Reduced 15.38%	11 $0
Q2 2023 Aug 10, 2023	BUY	$3.95 - $7.74 $51 - $100	13 New	13 $0
Q2 2022 Aug 10, 2022	SELL	$4.51 - $7.39 $94 - $155	-21 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$11.76 - $19.51 $3,680 - $6,106	-313 Reduced 93.71%	21 $0

Q2 2021 Aug 02, 2021	SELL	$18.95 - $23.95 $136,458 - $172,463	-7,201 Reduced 95.57%	334 $6,000
Q1 2021 May 13, 2021	BUY	$21.56 - $30.66 $1,724 - $2,452	80 Added 1.07%	7,535 $164,000
Q4 2020 Feb 10, 2021	SELL	$24.81 - $30.33 $153,549 - $187,712	-6,189 Reduced 45.36%	7,455 $211,000
Q3 2020 Nov 12, 2020	BUY	$30.28 - $35.72 $285,479 - $336,768	9,428 Added 223.62%	13,644 $428,000
Q2 2020 Aug 14, 2020	SELL	$24.08 - $33.35 $264 - $366	-11 Reduced 0.26%	4,216 $134,000
Q1 2020 May 18, 2020	BUY	$18.86 - $37.36 $79,721 - $157,920	4,227 New	4,227 $103,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.47B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.